Program Drives Digital and Omnichannel Engagement for Medical Science Liaison Teams & Medical Conferences MORRISVILLE, N.C., March 27, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of Medical
Collaboration Will Leverage Data Analytics and AI to Accelerate Clinical Trial Execution MORRISVILLE, N.C., March 22, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with KX, maker
Collaboration Leverages AI-ready Technology to Speed Asset Development and Optimize Performance MORRISVILLE, N.C., March 20, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic multi-year agreement
Newly Established Network Will Enable High Quality DCTs & Digital Health Technology Solutions MORRISVILLE, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of a Decentralized
Revenue for the fourth quarter of $1,359.9 million decreased 1.0% on a reported basis and increased 1.7% on a constant currency basis year-over-year. Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $470.1 million for the fourth
MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, prior to its earnings call at 8:00 a.m. ET.
MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Equicare to use proXimity™, an innovative cloud-based software platform that accelerates the transfer
Combined Capabilities Will Help Improve Trial Lifecycles for Patients, Sites & Sponsors MORRISVILLE, N.C., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Haystack
Partnership to Provide Cell and Gene Industry Integrated Solution including Cryoport's IntegriCell™ platform, and Supply Chain Services NASHVILLE, Tenn. , Jan. 18, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (" Cryoport "), a leading global provider of innovative temperature-controlled
Relationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial Solutions MORRISVILLE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Fosun
Despite Uncertainties, Survey Hints that Dealmaking Intensity Could Be Poised for a Rebound After a Year of Inertia MORRISVILLE, N.C., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 13 th annual
Reaffirms Full-Year 2022 Revenue Guidance MORRISVILLE, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that, effective March 31, 2023, Jason Meggs will transition from his role as Chief
MORRISVILLE, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe is scheduled to present at the 41 st Annual J.P.
